Compare Novo Nordisk A/S (NVO) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Carparts.Com Inc — how do they compare? Novo Nordisk A/S trades at $49.31 (market cap $220.53B), while Carparts.Com Inc trades at $5.09 (market cap $41.22M). The key difference: Novo Nordisk A/S is far larger — about 5350.1× Carparts.Com Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| NVO | PRTS | |
|---|---|---|
Market Cap | $220.53B | $41.22M |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $11.40 |
52-Week Low | $35.29 | $3.88 |
Enterprise Value | $239.49B | $56.19M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
PRTS trades at $4.85, down 8.49% today, reflecting a bearish technical trend. The company reported a net loss of $50.44M in 2025 despite revenue of $547.53M, with negative cash flow from operations. Recent developments include a reverse stock split and a new $25M credit facility, while analysts maintain a 60% buy rating. The stock shows oversold conditions with RSI levels below 30, indicating potential for a near-term bounce.
The outlook remains challenging due to persistent losses and negative cash flow, though cost-cutting measures and recent earnings beats offer some optimism. Key risks include execution on profitability and competitive pressures. The stock presents a high-risk opportunity for investors betting on a turnaround, supported by analyst bullishness but tempered by fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
